Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218153 · ClinicalTrials.gov registry record · Phase 3
Naltrexone Augmentation of Nicotine Patch Therapy - 1
A Phase 3 study of Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00218153: Completed Phase 3 study of Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
NCT00218153 is a Phase 3 study of Tobacco Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 200 participants, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218153, a Phase 3 study of Tobacco Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Naltrexone Augmentation of Nicotine Patch Therapy
Conditions Studied
Interventions
- DRUG Naltrexone
Study Locations (2)
Connecticut
- Substance Abuse Treatment Unit - New Haven
- VA Connecticut Health Care System - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2000-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
What the finished NCT00218153 record still lists
NCT00218153 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone is the first listed.
NCT00218153 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00218153 about?
NCT00218153 is a clinical study titled "Naltrexone Augmentation of Nicotine Patch Therapy - 1". Naltrexone Augmentation of Nicotine Patch Therapy
What is the current status of trial NCT00218153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2000-11. Estimated completion is 2004-04.
What conditions does trial NCT00218153 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00218153?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00218153?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218153 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00218153's enrollment target sits among peer trials
200 21st of 70 higher than 47 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabis-Tobacco Co-Use Treatment Study
RECRUITING · Phase 3
-
Non-Nicotine Agents for Smoking Cessation
COMPLETED · Phase 3
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia